Rahlfs Capital LLC Invests $1.06 Million in Pfizer Inc. (NYSE:PFE)

Rahlfs Capital LLC acquired a new stake in Pfizer Inc. (NYSE:PFE - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 39,953 shares of the biopharmaceutical company's stock, valued at approximately $1,060,000. Pfizer comprises approximately 1.0% of Rahlfs Capital LLC's investment portfolio, making the stock its 28th biggest position.

Other hedge funds have also recently added to or reduced their stakes in the company. Hurley Capital LLC bought a new stake in Pfizer in the fourth quarter valued at approximately $86,000. Ted Buchan & Co bought a new stake in shares of Pfizer in the 4th quarter valued at $700,000. Wedbush Securities Inc. raised its stake in Pfizer by 2.9% during the 4th quarter. Wedbush Securities Inc. now owns 202,238 shares of the biopharmaceutical company's stock worth $5,365,000 after buying an additional 5,697 shares during the period. Perennial Investment Advisors LLC lifted its holdings in Pfizer by 49.0% during the fourth quarter. Perennial Investment Advisors LLC now owns 24,920 shares of the biopharmaceutical company's stock worth $661,000 after acquiring an additional 8,195 shares in the last quarter. Finally, Grantham Mayo Van Otterloo & Co. LLC grew its stake in Pfizer by 21.0% in the fourth quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 2,676,738 shares of the biopharmaceutical company's stock valued at $71,014,000 after acquiring an additional 464,885 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was bought at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 0.06% of the stock is owned by company insiders.

Remove Ads

Analyst Ratings Changes

A number of research firms have recently commented on PFE. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Bank of America reissued a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Finally, Guggenheim reissued a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Stock Down 5.4 %

PFE stock traded down $1.30 during mid-day trading on Friday, reaching $22.99. The company had a trading volume of 79,829,399 shares, compared to its average volume of 39,460,357. The company has a market capitalization of $130.39 billion, a price-to-earnings ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 52 week low of $22.95 and a 52 week high of $31.54. The stock has a 50 day simple moving average of $25.87 and a two-hundred day simple moving average of $26.72. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same period last year, the business earned $0.10 earnings per share. The firm's revenue was up 24.7% on a year-over-year basis. As a group, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.